Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | CPT2 | P23786 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11137948 | 1.00 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL3006635 | 0.91 | MEN1 (0.77) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL29392875 | 0.87 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL30555786 | 0.87 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Hydrochloric Acid SCHEMBL11063351 | 0.86 | MEN1 (0.53) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL28508907 | 0.85 | MEN1 (0.73) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL28007625 | 0.85 | LMNA (0.67) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL27829739 | 0.85 | LMNA (0.67) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL7048157 | 0.84 | MEN1 (0.77) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL7763799 | 0.84 | MEN1 (0.77) | MEN1KMT2ACYP2C19RECQLCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-9421262-B2 | Compositions and methods for treating dermatological conditions | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | claimed |
| US-20110098229-A1 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | BIOMED RESEARCH & TECHNOLOGIES, INC. | 2011-04-28 | — | — | US | claimed |
| EP-1098630-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | Biomed Research and Technologies, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6149924-A | FOR TOPICAL APPLICATION | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000004870-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) | 2000-02-03 | — | — | WO | claimed |
| US-4415589-A | Use of carnitine and of lower acyl-carnitines in the therapeutic treatment of the pathology of the veins | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1983-11-15 | — | — | US | claimed |
| US-4194006-A | ANTIARRHYTHMIA | CAVAZZA CLAUDIO (IT) | 1980-03-18 | — | — | US | claimed |
| EP-3730131-B1 | TREATMENT OF BRAIN CANCER BY CONTINUOUS INFUSION OF COENZYME Q10 | BPGBIO INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BPGBIO INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | BPGBIO INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-2983654-B1 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGBIO INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | BPGBIO, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2000004870-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0793962-B1 | Medicament containing a carnitine derivative for treating arteriosclerosis obliterans | SIGMA TAU IND FARMACEUTI (IT) | 1999-12-08 | — | — | EP | disclosed |
| US-5811457-A | Therapeutical method for treating chronic arteriosclerosis obliterans | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-09-22 | — | — | US | disclosed |
| EP-0793962-A1 | Medicament containing a carnitine derivative for treating arteriosclerosis obliterans | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1997-09-10 | — | — | EP | disclosed |
| US-4415589-A | Use of carnitine and of lower acyl-carnitines in the therapeutic treatment of the pathology of the veins | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1983-11-15 | — | — | US | disclosed |
| US-4194006-A | ANTIARRHYTHMIA | CAVAZZA CLAUDIO (IT) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | VEGFA, NDUFA10, NDUFB10 | MEN1 569/4885KMT2A 2470/4885CYP2C19 220/4885 |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFA10, NDUFB10, NDUFA5 | MEN1 569/4885KMT2A 1396/4885CYP2C19 192/4885 |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | NDUFB10, NDUFA10, NDUFB5 | MEN1 526/4885KMT2A 644/4885CYP2C19 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.